Daniel M. Geynisman, MD

Daniel M. Geynisman, MD

Request an Appointment

Clinical Locations

  • Fox Chase Cancer Center
    333 Cottman Avenue
    Philadelphia, PA 19111
    Phone: 888-369-2427

Chief, Division of Genitourinary Medical Oncology

Associate Professor, Department of Hematology/Oncology

Vice Chair, Quality Improvement Program

NCCN, Testicular Cancer Panel Member

Specialties

  • Genitourinary Medical Oncology

Areas of Expertise

Penile Cancer, Ureteral Cancer, Kidney Cancer, Testicular Cancer, Bladder Cancer, Prostate Cancer, Urethral Cancer, Adrenal Tumor

Treatment Focus

Chemotherapy, targeted therapy, immunotherapy, hormone therapy, clinical trials for genitourinary malignancies

Research Program

Distinctions

Language(s) Other than English

  • Russian

Treatment Philosophy

I am a medical oncologist specializing in genitourinary cancers.  I became a physician and an oncologist for many reasons including the ability to sometimes cure life-threatening illness, having the opportunity to care for ill patients, and being a part of a rapidly evolving and improving field.  But perhaps the most important reason for entering oncology for me was the chance to build deep relationships with patients and their families at a time when they are the most vulnerable and in need, to be their advocate and resource, to guide them through a grueling time and hope with them for the best.  

I believe that every cancer patient deserves the utmost compassionate, individualized, expert and prompt care.  I came to Fox Chase after completing my fellowship at the University of Chicago because here I can offer just that. By working together with each patient, their family and a team of my expert colleagues, we can harness the most recent advances in oncology for each patient.

In my clinical practice I focus on the care of patients with prostate, kidney, bladder, penile, adrenal and testicular cancer and I am proud to be part of a large multidisciplinary team of distinguished clinicians and researchers at Fox Chase.  Over the last decade, the number of treatment options for patients with advanced cancers has greatly expanded and at Fox Chase we can offer both the latest standard-of-care as well as new experimental approaches. My particular research interest is in health outcomes as well as clinical trials development for genitourinary cancers.

A cancer diagnosis is one of the most difficult times in a person’s life; my primary goal is to bring together all the resources of a cutting-edge cancer center to the patient in a compassionate and individualized manner.

Educational Background

  • Fellow, Maclean Center for Clinical Medical Ethics, University of Chicago, Chicago, IL
  • Fellow and Chief Fellow, Hematology and Medical Oncology, University of Chicago Medical Center, Chicago, IL
  • Intern, Resident and Chief Resident, University of Pittsburgh Medical Center, Pittsburgh, PA
  • MD, University of Pittsburgh, Pittsburgh, PA, 2006

Certifications

  • American Board of Internal Medicine - Adolescent Medicine

Memberships

  • American Society of Clinical Oncology

Honors & Awards

  • Philadelphia Magazine Top Doctors,2023-2024
  • ASCO/AACR Methods in Clinical Research Workshop Selected Participant, Vail, CO, 2014   
  • Illinois Medical Oncology Society Fellows Award, Chicago, Illinois, 2012 
  • Senior Presentation Award, University of Pittsburgh School of Medicine Department of  Medicine, 2009   
  • Lucien J. Rubenstein Memorial Award, American Brain Tumor Association, 2003 
  • Morris H. and Gertrude M. Harris Foundation Scholarship, University of Pittsburgh School of Medicine, Pittsburgh, PA, 2002–2006
Link to /sites/default/files/styles/patient_story/public/images/patient-stories/PHilSanchezHeadshot-resize.jpg?h=261d95a3&itok=NfCRQqdO

Felix (Phil) Sanchez

  • Bladder Cancer

I follow up with people and act as a mentor. I let them know they are able to contact me at any time, and I can offer them peace of mind from someone who has been where they are headed.

VIEW PATIENT STORY
Link to /sites/default/files/styles/patient_story/public/images/patient-stories/Bill%20Doyle%20Profile_0.jpg?h=4a436e04&itok=MCRBQovr

Bill Doyle

  • Bladder Cancer

Bill Doyle always knew he wanted to be on the radio. As one half of the Deminski & Doyle talk radio show on New Jersey 101.5, life was good for Bill until he was diagnosed with bladder cancer at 52. After surgery and several rounds of chemotherapy, Bill is back on the airwaves, thanks in part to the support of his family and the countless 101.5 listeners who have offered words of support during his cancer journey.

VIEW PATIENT STORY
Link to /sites/default/files/styles/patient_story/public/images/patient-stories/barrybanner.jpg?h=dbb571bb&itok=NcI-gxEx

Barry Taitelman

  • Kidney Cancer

Becoming a grandfather was something I had been looking forward to for years. But just before I learned that my daughter-in-law was pregnant, I was diagnosed with Stage 4 kidney cancer. I couldn’t bear the thought of getting to know my grandson and then not getting to be there to watch him grow up.

VIEW PATIENT STORY

Research Interests

  • Drug development for genitourinary malignancies
  • Health outcomes/services research
  • Medical ethics

Selected Publications

Geynisman D.M., Du E.X., Yang X., Sendhil S.R., Tejo V.D., Betts K.A.,Huo S., Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma. Future Oncol. 18(10): 1219-1234, 2022.  https://www.ncbi.nlm.nih.gov/pubmed/34939424.

Geynisman D.M., Kadow B.T., Shuch B.M., Boorjian S.A., Matin S.F., Rampersaud E., Milestone B.N., Plimack E.R., Zibelman M.R., Kutikov A., Smaldone M.C., Chen D.Y., Viterbo R., Joshi S., Greenberg R.E., Malizzia L., McGowan T., Ross E.A.,Uzzo R.G., Sporadic angiomyolipomas (amls) growth kinetics while on everolimus (sage): Results of a phase ii trial. J Urol. 204(3): 531-537, 2020. PMC7695484. https://www.ncbi.nlm.nih.gov/pubmed/32250730.

Strother M.C., Kutikov A., Epstein M., Bochner E., Deng M., Handorf E., Lewis B., Ghatalia P., Greenberg R.E., Chen D., Viterbo R., Anari F., Smaldone M.C., Zibelman M.R., Uzzo R.G., Plimack E.R., Geynisman D.M., Safety of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer and malignant ureteric obstruction. BJU Int. 129(3): 364-372, 2022. https://www.ncbi.nlm.nih.gov/pubmed/33780097.

Changa NM, Xie WL, Bilen MA, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LC. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncology, 20(4):581-90, 2019.

Rouvinov K, Plimack ER, Zibelman M, Ghatalia P, Geynisman DM. Update on perioperative systemic therapy for urothelial carcinoma. Clinical advances in hematology & oncology : H&O, 17(3):176-83, 2019.

Martinez Chanza N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LC. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. The Lancet Oncology, 2019.

Correa AF, Handorf E, Joshi SS, Geynisman DM, Kutikov A, Chen DY, Uzzo RG, Viterbo R, Greenberg RE, Smaldone MC. Differences in Survival Associated with Performance of Lymph Node Dissection in Patients with Invasive Penile Cancer: Results from the National Cancer Database. J Urol, 199(5):1238-44, 2018. PubMed

Geynisman DM, Abbosh PH, Plimack ER, Zibelman M. Chemoimmunotherapy in Metastatic Urothelial Carcinoma. Eur Urol, 2018. 

Joshi SS, Handorf E, Strauss D, Correa AF, Kutikov A, Chen DYT, Viterbo R, Greenberg RE, Uzzo RG, Smaldone MC, Geynisman DM. Treatment Trends and Outcomes for Patients With Lymph Node-Positive Cancer of the Penis. JAMA Oncol, 2018. 

Geynisman DM, Ross EA, Plimack ER. Osteoclast Inhibitors in Advanced Prostate Cancer: Does the Benefit Extend Beyond Skeletal-Related Events? Eur Urol. 2015 Oct;68(4):578-80. doi: 10.1016/j.eururo.2015.06.009. Epub 2015 Jun 23. PubMed

... Expand

Additional Publications

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.

Ratings Breakdown

Loading ...

Patient comments

Loading ...